Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.59), $0.05 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $962 thousand versus the consensus estimate of $960 thousand.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.